Jeuveau maker hits profitability milestone on $84M revenue, raising full-year guidance and signaling margin expansion ahead.
Evolus reported Q2 revenue of $84.08M with break-even earnings (EPS $-0.12), a critical inflection point for the toxin-focused company. The result reflects disciplined cost management and pricing power in the Jeuveau franchise, which has stabilized after aggressive discounting cycles. Analyst upgrades from Stifel and Wall Street Zen followed, with maintained buy ratings and $17 price targets.
The company raised 2026 guidance on the back of Q2 performance, signaling confidence in sustained profitability. For practice owners, Evolus' trajectory matters: as the company moves from cash-burn to cash-generation, its ability to fund rebate programs, loyalty initiatives, and market development spending becomes clearer. The break-even milestone also reduces refinancing risk and strengthens negotiating leverage with group purchasing organizations.
Evolus hit break-even in Q2 on $84M revenue, raising full-year guidance and signaling margin expansion.
Evolus has now posted three consecutive profitable quarters, a reversal from its 2024-2025 cash-drain phase.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
